Drug intelligence / Profile preview

dexmedetomidine + magnesium sulphate + bupivacaine

Development stage: Unknown
Lead developer: Orion Pharma
Modality: Small Molecules
Administration: Epidural, Intrathecal, Perineural, Caudal, Intraarticular, Local Infiltration

Overview

This is a combination of three agents used in anesthesia and pain management. Bupivacaine is an amide local anesthetic that blocks nerve impulse generation and conduction by inhibiting voltage-gated sodium channels. Magnesium sulphate acts as an NMDA receptor antagonist with antinociceptive effects. Dexmedetomidine is an alpha-2 adrenergic receptor agonist with sedative and analgesic properties. The combination may provide enhanced and prolonged analgesia compared to individual components.

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)ADRA2A (α2A)NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on dexmedetomidine + magnesium sulphate + bupivacaine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dexmedetomidine + magnesium sulphate + bupivacaine.

Explore the full profile